Could herbal pills cut eye injections for wet AMD? new trial launches
NCT ID NCT07269769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will receive either the herbal pills or a placebo, plus one initial injection. The main goal is to see if the pills help control the disease with fewer injections over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sanhuang Jingshiming Pills (herbal pills) plus ranibizumab injections
What this could lead to
If successful, this combination could reduce the number of eye injections needed for wet age-related macular degeneration, easing treatment burden.
What could go wrong
This is an early-stage trial with 450 participants, and the herbal pill's benefits are unproven. Results may not show a clear advantage over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••